Dr. Kenneth E. Fleisher, DDS, FACS
2 MCE Credits
Bone health and maintenance of bone integrity are important concerns during
comprehensive cancer care and management of osteoporosis. Bisphosphonates
and denosumab are antiresorptive medications widely used for the prevention
and treatment of osteoporosis and skeletal complications associated with
metastatic cancer and multiple myeloma. Medication-related osteonecrosis of
the jaw (MRONJ) related to antiresorptive therapy is a condition that has created
numerous dilemmas in patient management and may have a broad health
impact.
Minimizing the risk of MRONJ is critical, not only to prevent MRONJ but also to
maximize the benefit of antiresorptive therapy. This case-based presentation will
review evidence-based data that has led to paradigm shifts for pathogenesis and
innovative strategies for risk assessment, prevention and management of
MRONJ.
Objectives
The participant will learn:
1. Strategies for diagnosis of MRONJ related to clinical presentation, imaging
and differential diagnosis.
2. Risk assessment and prevention related to dental treatment: What works and
what doesn’t.
3. Recent advances in pathogenesis: What we know today and how this may
impact clinical decisions.
4. Strategies for improving oral health and function via dentoalveolar surgery,
restorative dentistry and implant surgery.
5. Management options for patients with MRONJ.
Course is sponsored by The Fifth District Dental Society
The Fifth District Dental Society designates this activity for 2 continuing education credits. The Fifth District Dental Society is an ADA CERP recognized provider approved by the New York State Dental Association. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
